171 related articles for article (PubMed ID: 10348793)
1. Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats.
Tateishi T; Watanabe M; Nakura H; Tanaka M; Kumai T; Sakata SF; Tamaki N; Ogura K; Nishiyama T; Watabe T; Kobayashi S
Drug Metab Dispos; 1999 Jun; 27(6):651-4. PubMed ID: 10348793
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
3. Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats.
Nagata M; Hidaka Y; Hatakeyama K; Kawano Y; Iwakiri T; Okumura M; Arimori K
Biopharm Drug Dispos; 2011 Mar; 32(2):126-30. PubMed ID: 21341281
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
5. Parenteral nutrition decreases hepatic dihydropyrimidine dehydrogenase activity and modulates catabolism of 5-fluorouracil in rats.
Taniguchi M; Yano M; Tsujinaka T; Ogawa A; Morita S; Kaneko K; Akiyama Y; Miki H; Monden M
In Vivo; 2003; 17(3):219-23. PubMed ID: 12929570
[TBL] [Abstract][Full Text] [Related]
6. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of two fluorouracil administration regimens for colorectal cancer.
Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
[TBL] [Abstract][Full Text] [Related]
8. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice.
Innocenti F; Danesi R; Bocci G; Natale G; Del Tacca M
Toxicol Appl Pharmacol; 2005 Mar; 203(2):106-13. PubMed ID: 15710171
[TBL] [Abstract][Full Text] [Related]
9. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
10. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Ogura K; Kato A; Takubo H; Watabe T
J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
[TBL] [Abstract][Full Text] [Related]
11. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).
Milano G; Etienne MC
Anticancer Res; 1994; 14(6A):2295-7. PubMed ID: 7825962
[TBL] [Abstract][Full Text] [Related]
12. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
[TBL] [Abstract][Full Text] [Related]
13. Regulation of dihydropyrimidine dehydrogenase gene expression in regenerating mouse liver.
Yamada H; Fukushima M; Koizumi K; Katakura H; Nakanishi H; Teshima S; Kamiyama Y; Ikenaka K
Int J Oncol; 2003 Feb; 22(2):359-64. PubMed ID: 12527935
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.
Jiang W; Lu Z; He Y; Diasio RB
Clin Cancer Res; 1997 Mar; 3(3):395-9. PubMed ID: 9815697
[TBL] [Abstract][Full Text] [Related]
16. [Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].
Etienne MC; Milano G; Fleming RA; Thyss A; Renée N; Schneider M; Demard F
Bull Cancer; 1992; 79(12):1159-63. PubMed ID: 1304835
[TBL] [Abstract][Full Text] [Related]
17. Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation.
García-Ayllón MS; Silveyra MX; Candela A; Compañ A; Clària J; Jover R; Pérez-Mateo M; Felipo V; Martínez S; Galcerán J; Sáez-Valero J
Hepatology; 2006 Mar; 43(3):444-53. PubMed ID: 16496349
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
19. Renin and angiotensinogen mRNA expression in the kidneys of rats subjected to long-term bile duct ligation.
Ubeda M; Matzilevich MM; Atucha NM; García-Estañ J; Quesada T; Tang SS; Ingelfinger JR
Hepatology; 1994 Jun; 19(6):1431-6. PubMed ID: 8188173
[TBL] [Abstract][Full Text] [Related]
20. Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics.
Watanabe M; Tateishi T; Takezawa N; Tanaka M; Kumai T; Nakaya S; Kobayashi S
Cancer Chemother Pharmacol; 2001 Mar; 47(3):250-4. PubMed ID: 11320669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
